Merck Collaborates with Innovative Biotech to Support Establishment of First Vaccine Production Facility in Nigeria
Merck announced that it has signed an agreement with biotechnology company Innovative Biotech (IB) to design the manufacturing process for the first vaccine production facility in Nigeria.

Merck KGaA
“We are committed to expanding access to life-saving and life-enhancing therapies to patients across the world and this collaboration is a testament to that commitment,” said Andrew Bulpin, Head of Process Solutions, Life Science business sector at Merck. “We are proud to provide the technical support and expertise that could help enable the first vaccine facility in Nigeria and localize vaccine development in the West Africa region.”
This collaboration is part of the West African pandemic readiness program, which aims to localize vaccine development in the African nations. The first phase of this integrated partnership focuses on designing the fill and finish facility, incorporating the company’s Mobius® single-use technology, while the second phase will focus on enabling continuous manufacturing.
“By leveraging Merck’s facility design expertise, we’ll be able to build the first vaccine production facility in Nigeria and manufacture high-quality and affordable vaccines locally,” said Simon Agwale, CEO of Innovative Biotech.
Innovative Biotech’s licensor, TechnoVax, is developing a virus-like-particle (VLP)-based vaccine to target variants of Covid-19. Provisional results from the preclinical studies of the VLP-based vaccine have shown promise for virus neutralization. Technovax is a 2019 recipient of Life Science’s Advance Biotech Grant for developing a virus-like particle platform that facilitates the development and production of a range of vaccines targeting the prevention of respiratory diseases, hemorrhagic fevers, immunodeficiency and cancers.
The Life Science business sector has been supporting Innovative Biotech’s effort with its BioReliance® testing services, technical transfer support and single-use facility design. This partnership showcases the company’s commitment to supporting the building of manufacturing capabilities in the Middle East and Africa.
Most read news
Organizations
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

ZEISS to acquire LENSO Sp. z o.o. to strengthen market access and industry expertise in 3D metrology and inspection solutions in Poland
Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Hospital-Acquired Pneumonia
CRISPR/Cas9 Silences Gene Associated with High Cholesterol
Genetic causes of canine mammary tumors
Evolva reaches milestone in BASF collaboration
MedGenome secures series C funding

Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse - The manufacturing facility is expected to be operational in H2 2024 and will create upwards of 150 new high-skill jobs

Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility - The new facility is planned to ensure that FUJIFILM Irvine Scientific can meet increasing market demands
